Topic: anti-diabetic drug
The expansion is driven by midphase Type 2 diabetes data suggesting tirzepatide improves markers associated with nonalcoholic steatohepatitis.
A team of Stanford University scientists has found a way to direct a regenerative diabetes medicine to the right cells more precisely.
Novo Nordisk has signed another deal intended to keep it at the top of the tree when it comes to developing new diabetes and obesity drugs.
Japanese Big Pharma Takeda and U.S. partner Zinfandel Pharmaceuticals have decided to give up and stop testing a 20-year-old diabetes medicine.
Eli Lilly is paying $55 million upfront for the rights to KeyBioscience’s pipeline of treatments for Type 2 diabetes and other metabolic conditions.